Literature DB >> 8271037

Absorbed fractions for electrons and beta particles in spheres of various sizes.

J A Siegel1, M G Stabin.   

Abstract

UNLABELLED: The use of electron-emitting radionuclides in tumor imaging and therapy has presented some new challenges to conventional radiation dosimetry. The fraction of electron energy absorbed in most source regions has usually been assumed to be unity. In small structures such as localized tumors or isolated regions containing moderate to high energy electron emitters, however, this may not always be the case.
METHODS: Using an extension of Berger's scaled absorbed dose distributions for point sources to represent a spherical geometry, absorbed fractions of electron energy for sources uniformly distributed in spheres of various sizes have been calculated.
RESULTS: Beta particle and monoenergetic electron energies studied range from 0.025 to 4.0 MeV and sphere masses range from 0.01 to 1000 g. S values have also been calculated for 90Y, 123I and 131I based on the results of the absorbed fraction calculations.
CONCLUSION: These calculated absorbed fractions are valuable in estimating electron energy loss from small spherical structures and may be useful in estimating the radiation dose to these small volumes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8271037

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Authors:  Katharina Seystahl; Veit Stoecklein; Ulrich Schüller; Elisabeth Rushing; Guillaume Nicolas; Niklaus Schäfer; Harun Ilhan; Athina Pangalu; Michael Weller; Jörg-Christian Tonn; Michael Sommerauer; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

2.  Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

Authors:  Kelly Davis Orcutt; Adrian L Slusarczyk; Maryelise Cieslewicz; Benjamin Ruiz-Yi; Kumar R Bhushan; John V Frangioni; K Dane Wittrup
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

3.  Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.

Authors:  Yusuf Menda; M Sue O'Dorisio; Simon Kao; Geetika Khanna; Stacy Michael; Mary Connolly; John Babich; Thomas O'Dorisio; David Bushnell; Mark Madsen
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

4.  Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms.

Authors:  Keamogetswe Ramonaheng; Johannes A van Staden; Hanlie du Raan
Journal:  Heliyon       Date:  2022-07-06

5.  Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours.

Authors:  Jeffrey L Schaal; Jayanta Bhattacharyya; Jeremy Brownstein; Kyle C Strickland; Garrett Kelly; Soumen Saha; Joshua Milligan; Samagya Banskota; Xinghai Li; Wenge Liu; David G Kirsch; Michael R Zalutsky; Ashutosh Chilkoti
Journal:  Nat Biomed Eng       Date:  2022-10-19       Impact factor: 29.234

6.  Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

Authors:  A Romer; D Seiler; N Marincek; P Brunner; M T Koller; Q K T Ng; H R Maecke; J Müller-Brand; C Rochlitz; M Briel; C Schindler; M A Walter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

7.  Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.

Authors:  Matthew J Schipper; Kenneth F Koral; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2012-09       Impact factor: 3.099

8.  Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Authors:  Johnnie J Orozco; Ethan R Balkin; Ted A Gooley; Aimee Kenoyer; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Mark D Hylarides; Mazyar Shadman; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

9.  Organ-specific SPECT activity calibration using 3D printed phantoms for molecular radiotherapy dosimetry.

Authors:  Andrew P Robinson; Jill Tipping; David M Cullen; David Hamilton; Richard Brown; Alex Flynn; Christopher Oldfield; Emma Page; Emlyn Price; Andrew Smith; Richard Snee
Journal:  EJNMMI Phys       Date:  2016-07-13

10.  Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity.

Authors:  Jonas Högberg; Magnus Rizell; Ragnar Hultborn; Johanna Svensson; Olof Henrikson; Johan Mölne; Peter Gjertsson; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2015-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.